Physician profile
Scott C Parrish
NPI 1073672390
$11,847.59
in general payments reported to CMS, 2019-2025
20 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,608 · 2020: $602 · 2021: $649 · 2022: $71.99 · 2023: $489 · 2024: $5,979 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,924 · Education: $2,585 · Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,923.64 |
| Education | $2,584.99 |
| Food and Beverage | $1,408.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,627.29 | 2024 | |
| Pinnacle Biologics, INC | $3,417.15 | 2019-2025 | Photofrin |
| Ethicon INC. | $1,771.26 | 2019-2024 | Monarch Platform |
| Csa Medical, INC | $146.35 | 2020 | |
| Inogen, INC. | $114.93 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Galvanize Therapeutics, INC | $105.33 | 2025 | Aliya System |
| Glaxosmithkline, LLC. | $103.07 | 2020-2025 | Nucala |
| Inspire Medical Systems, INC. | $99.04 | 2023-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $84.99 | 2025 | |
| Pulmonx Corporation | $64.03 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.43 | 2025 | Jascayd |
| Verona Pharma, INC. | $52.65 | 2025 | Ohtuvayre |
| Steris Corporation | $38.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $29.66 | 2020-2023 | Fasenra |
| Covidien LP | $28.98 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $25.87 | 2024 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $24.92 | 2025 | Glassia |
| Avadel Cns Pharmaceuticals, LLC | $22.14 | 2025 | Lumryz |
| United Therapeutics Corporation | $20.70 | 2024 | Tyvaso |
| Insmed, INC. | $13.80 | 2025 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.